Description
TB-500 FRAG is the active heptapeptide fragment of Thymosin Beta-4 (Tβ4) - the short sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln (LKKTETQ, amino acids 17 to 23) responsible for the wound healing and angiogenesis action of TB-500. Instead of administering the complete 43-amino-acid Tβ4 molecule, the FRAG form delivers only the bioactive region.
Per study reports TB-500 FRAG binds to G-actin and modulates its polymerization - this is the central mechanism of actin mobilization in cell migration. The result is accelerated wound healing, improved endothelial migration and angiogenesis stimulation.
The FRAG form has two theoretical advantages over full TB-500: better tissue penetration due to smaller molecule size and potentially higher bioavailability per mg. Direct comparison studies between FRAG and full TB-500 are limited - most data comes from full-molecule TB-500 research.
Typical application is subcutaneous two to three times per week in 6-8 week healing courses.
You can order TB-500 FRAG as lyophilized peptide in 10-pack at 10mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
TB-500 FRAG is considered well tolerated per study reports. The heptapeptide fragment shares the mild profile of the parent compound TB-500, though specific data on the FRAG form itself is limited.
Observed in research and user reports:
- Injection site: mild redness, pressure or transient irritation at the injection site with subcutaneous use.
- Circulation: isolated reports of brief fatigue or mild dizziness shortly after application.
- Angiogenesis effect: because the fragment is described in the literature as stimulating angiogenesis, a theoretical concern is discussed that existing abnormal tissue could also be supplied. Evidence is lacking. The point remains part of the research discussion.
- Thin data on the FRAG form: direct comparative studies between FRAG and full TB-500 are limited. Robust long-term human studies do not exist. The safety profile is largely derived from full-molecule TB-500 research.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- The regenerative peptide thymosin beta-4 accelerates the rate of dermal healing in preclinical animal models and in patients - Annals of the New York Academy of Sciences 2012, Treadwell et al: documents accelerated wound healing in animal models and phase-2 patient cohorts.
- Interaction of thymosin beta-4 with muscle and platelet actin: implications for actin sequestration in resting platelets - Biochemistry 1992, Weber et al: biochemical evidence for 1:1 G-actin binding, the core mechanism of FRAG action.
- The control of actin nucleotide exchange by thymosin beta 4 and profilin - Molecular Biology of the Cell 1992, Goldschmidt-Clermont et al: regulation of actin polymerization relevant to cell migration.
- Thymosin Beta-4 induces hair growth via stem cell migration and differentiation - Annals NYAS 2007, Philp et al: migration-driven effect at stem-cell level.
- Thymosin beta-4 and venous ulcers - Annals NYAS 2007, Guarnera et al: clinical healing effect in chronic wounds.
